Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

1.895
+0.0703.84%
Volume:23.19M
Turnover:43.41M
Market Cap:7.57B
PE:10.21
High:1.895
Open:1.815
Low:1.815
Close:1.825
52wk High:3.690
52wk Low:1.690
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:1.04
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.186
ROE:4.27%
ROA:2.18%
PB:0.42
PE(LYR):10.21
PS:1.06

Loading ...

Luye Pharma H1 2026: Net Profit Climbs 6.5% Despite 5.6% Revenue Dip; CNS Portfolio Drives Growth

Bulletin Express
·
Sep 29

Shandong Boan Biotech Files HKEX Next-Day Disclosure Reporting Share Repurchase for Treasury Shares

Reuters
·
Sep 11

Shandong Boan Biotech Confirms RMB 75 Million Finance Lease Asset Sale Price in Supplemental Pact

Reuters
·
Sep 09

Shandong Boan Biotech Files HKEX Next-Day Disclosure Return on Share Buyback Cancellation

Reuters
·
Sep 09

METIS TECHBIO-P Jumps 7% After Strategic Pact and Stock Connect Inclusion

Stock News
·
Sep 08

Shandong Boan Biotech Files HKEX Next-Day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Sep 07

Shandong Boan Biotech Files HKEX Next-Day Return Disclosing Share Buyback

Reuters
·
Sep 04

多部委联合发布房地产新政,美联储主席鹰派信号引发市场关注

Stock News
·
Aug 31

Luye Pharma H1 2026: Revenue Drops 5.6 % to RMB 3.00 B, Net Profit Climbs 6.5 % on Lower Costs; CNS Therapies Lead Growth

Bulletin Express
·
Aug 30

Shandong Boan Biotech Files HKEX Next-Day Return Disclosing Share Buyback at HKD 3.74 Each

Reuters
·
Aug 28

LUYE PHARMA: UBS Group AG Disposes of Shares, Long Position Falls to 12.98%

HK Disclosure
·
Aug 28

Shandong Boan Biotech Enters RMB 75 Million Sale-and-Leaseback Deal with Industrial Bank Financial Leasing

Reuters
·
Aug 27

Luye Pharma's Vaccine for Cervical Precancerous Lesions to Enter Phase II Trial

MT Newswires Live
·
Aug 21

Luye Pharma Sets 29 Aug 2026 Board Meeting to Approve 1H 2026 Results and Review Interim Dividend

Bulletin Express
·
Aug 17

Luye Pharma Schedules Board Meeting to Review Interim Results, Weigh Dividend

Reuters
·
Aug 17

Shandong Boan Biotech Completes China Phase Ia Trial of Ba1302 CD228-Targeted ADC

Reuters
·
Aug 14

Shandong Boan Biotech Schedules Board Meeting on Interim Results, Dividend Review

Reuters
·
Aug 14

Luye Pharma Completes US Bridging Trial for Neurological Drug Candidate

MT Newswires Live
·
Aug 06

Luye Pharma completes U.S. bridging trial for VMAT2/Sigma-1R dual-acting drug LY03015

Bulletin Express
·
Aug 05

Shandong Boan Files Brazil Marketing Application for Ba9101 Aflibercept Biosimilar with Anvisa

Reuters
·
Aug 05